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macrolides, ketolides or quinolones [9] was
maintained against isolates of the four Spanish
multiresistant clones.
In conclusion, resistance rates to levofloxacin
and cefotaxime were similar for amoxycillin-
susceptible and non-susceptible isolates, while
resistance rates to other cephalosporins and
macrolides were significantly higher among
amoxycillin-non-susceptible isolates. Isolates
belonging to the Spain14-5 and Spain6B-2 clones
were found most frequently among amoxycillin-
non-susceptible isolates.
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ABSTRACT
Plasmid-mediated quinolone resistance is being
reported increasingly worldwide among isolates
of enterobacteria. This resistance is mostly asso-
ciated with Qnr-like determinants that confer
resistance to quinolones, e.g., nalidixic acid, and
reduced susceptibility to fluoroquinolones. This
study investigated whether amino-acid substitu-
tions in QnrA1 and QnrS1 determinants might be
responsible for an enhancement of resistance to
quinolones and, particularly, to fluoroquinolones.
However, random and site-directed mutagenesis
failed to identify any single amino-acid substitu-
tion that could be responsible for higher levels of
resistance to quinolones or fluoroquinolones,
indicating that the selection of such mutants
in vivo is probably a rare event.
Keywords Escherichia coli, mutation, plasmid-medi-
ated, Qnr, quinolone resistance
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Several reports have described the worldwide
dissemination of plasmid-mediated quinolone
resistance (qnr) genes in Enterobacteriaceae [1–6].
This mechanism of resistance was first reported in
a multidrug-resistant isolate of Klebsiella pneumo-
niae from the USA [7]. The corresponding resist-
ance determinant, QnrA (now termed QnrA1), is a
protein of 218 amino-acids that belongs to the
pentapeptide repeat protein family [8,9]. Six var-
iants of QnrA (QnrA1–QnrA6) have now been
identified worldwide [9]. In addition, other plas-
mid-mediated Qnr-like determinants, e.g., QnrB
(six variants, QnrB1–QnrB6) and QnrS (two var-
iants, QnrS1 and QnrS2), have been identified that
share 40% and 59% identity, respectively, with
QnrA1 [10,11]. The QnrA proteins protect DNA by
preventing binding of quinolones to type II topo-
isomerases [12,13], thereby conferring resistance
to quinolones, e.g., nalidixic acid, and reduced
susceptibility to fluoroquinolones [8,9]. Saga et al.
[14] demonstrated that a single amino-acid sub-
stitution (C115Y) in a chromosomally encoded
Qnr-type determinant VPA0095 from Vibrio para-
haemolyticus (subsequently termed QnrVP [15])
was responsible for a significant enhancement of
resistance to quinolones when the responsible
gene was cloned and expressed in Escherichia coli.
Accordingly, the aims of the present study were:
(i) to investigate, using random mutagenesis,
whether amino-acid substitutions in QnrA1 and
QnrS1 determinants might be responsible for
increased levels of resistance to quinolones; and
(ii) to evaluate the role of a C115Y substitution in
QnrA1 and QnrS1 determinants (the sequences of
qnrB-like genes were not available at the begin-
ning of this study).
Whole-cell DNA from the qnrA1-positive E. coli
strain Lo [4] and the qnrS1-positive E. coli strain
S7 [5] was extracted using a standard procedure
[5]. Random mutations were generated in the
qnrA and qnrS genes using the Genemorph II
Random Mutagenesis Kit (Stratagene, La Jolla,
CA, USA.). The entire sequences of the qnrA1 and
qnrS1 genes were amplified using primers
PreQnrA2 (5¢-GATTAAAGGAAGCCGTATGG)
and QnrBH (5¢-CTAATCCGGCAGCACTATTA),
amplifying a 673-bp fragment containing the
qnrA1 gene of E. coli Lo, and primers PreQnrS-
A-S7 (5¢-ATTATTTGTTACAGACCCGG) and
PreQnrS-B-S7 (5¢-GCTAACTTTGCAACAGTG-
CC), amplifying a 1277-bp fragment containing
the qnrS1 gene of E. coli S7. The amplified frag-
ments were cloned in the kanamycin-resistant
pCR-BluntII-TOPO plasmid (Invitrogen Life
Technologies, Cergy-Pontoise, France) and trans-
formed into E. coli TOP10 (Invitrogen). Selection
of recombinant clones was made on agar plates
containing kanamycin 30 mg ⁄L and different
concentrations of nalidixic acid (8, 16, 32 and
64 mg ⁄L) or ciprofloxacin (0.25, 0.5, 1 and
2 mg ⁄L). Despite numerous attempts, recombi-
nant clones were not obtained, whereas wild-type
strains containing qnrA1- or qnrS1-like genes grew
as controls on kanamycin-containing plates.
To evaluate the role of a C115Y change
in increasing the resistance level to quinolones,
site-directed mutagenesis experiments were also
performed in isogenic strains. A single base-pair
change at codon 115 (TGT to TAT) in the qnrA1
and qnrS1 genes was introduced using recombi-
nant plasmids in conjunction with the Quickchange
site-directed mutagenesis kit (Stratagene) and
primers QnrA-Tyr1 (5¢-CCATAAGATGTAC-
TTCTACTCGGCTTATATCTCAGGTTGC) and
QnrA-Tyr2 (5¢-GCAACCTGAGATATAAGCC-
GAGTAGAAGTACATCTTATGG) for qnrA1, and
QnrS-Tyr1 (5¢-GTGAGTAATCGTATGTACTTTT-
ACTCAGCATTTATTTCTGGATGTAATCTTTCC)
and QnrS-Tyr2 (5¢-GGAAAGATTACATCCAG-
AAATAAATGCTGAGTAAAAGTACATACGA-
TTACTCAC) for qnrS1 (underlined bases indicate
the position of the change). The levels of expres-
sion of the qnrA1 and qnrS1 genes were identical,
since the recombinant plasmids harbouring the
wild-type and mutated qnr-like genes were
identical except for the single base-pair substitu-
tion at codon 115. MICs of quinolones for E. coli
TOP10 and its transformants were determined
using Etests (AB Biodisk, Solna, Sweden), which
were interpreted according to CLSI guidelines
[16]. MICs of quinolones and fluoroquinolones
for E. coli TOP10 harbouring recombinant
plasmids with mutated qnrA1 and qnrS1 genes
(pQnrA1 ⁄C115Y and pQnrS1 ⁄C115Y, respect-
ively) did not exceed those observed for E. coli
TOP10 harbouring recombinant plasmids with
wild-type qnrA1 and qnrS1 genes (pQnrA1 and
pQnrS1, respectively) (Table 1). In contrast, MICs
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of quinolones and fluoroquinolones for E. coli
TOP10 (pQnrA1 ⁄C115Y) and E. coli TOP10
(pQnrS1 ⁄C115Y) were slightly lower than those
for E. coli TOP10 harbouring qnrA1 and qnrS1
wild-type genes, respectively (Table 1). These
results were in contrast to those obtained by
Saga et al. [14] for QnrVP from V. parahaemolyti-
cus, for which the C115Y change resulted in a
significant increase in the MICs of quinolones and
fluoroquinolones.
Taken together, these results indicate that
specific amino-acid residues, e.g., that at position
115, may interact with either DNA or type II
topoisomerases when contributing to Qnr-
mediated quinolone resistance. A single amino-
acid substitution appears to be insufficient to
confer a significantly increased level of resistance
to quinolones and a broadened spectrum of
insusceptibility to fluoroquinolones. Indeed, it
can be hypothesised that multiple amino-acid
substitutions are necessary to obtain a protein
able to mediate fluoroquinolone resistance, and
that such proteins might be unstable or toxic for
the cell. It is possible that higher levels of
resistance to quinolones and fluoroquinolones
in a Qnr-like positive background may be difficult
to obtain in vivo without associated chromo-
somally-encoded mechanisms of resistance [17].
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Table 1. MICs of quinolones and fluoroquinolones for
reference strain Escherichia coli TOP10 and its transform-
ants harbouring recombinant plasmids pQnrA1 and
pQnrS1, expressing wild-type QnrA1 and QnrS1, respect-
ively, and recombinant plasmids pQnrA1 ⁄C115Y and
pQnrS1 ⁄C115Y, expressing modified QnrA1 and QnrS1
proteins containing the C115Y substitution, respectively
Antibiotic
MIC (mg ⁄L)
E. coli
TOP10
(pQnrA1)
E. coli TOP10
(pQnrA1 ⁄
C115Y)
E. coli
TOP10
(pQnrS1)
E. coli TOP10
(pQnrS1 ⁄
C115Y)
E. coli
TOP10
Nalidixic
acid
3 2 8 6 1
Ofloxacin 0.19 0.047 0.38 0.25 0.016
Ciprofloxacin 0.064 0.012 0.25 0.094 0.003
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17. Poirel L, Pitout JD, Calvo L, Rodriguez-Martinez JM,
Church D, Nordmann P. In vivo selection of fluoroqui-
nolone-resistant Escherichia coli isolates expressing
plasmid-mediated quinolone resistance and expanded-
spectrum b-lactamase. Antimicrob Agents Chemother 2006;
50: 1525–1527.
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ABSTRACT
The occurrence of three cases of meningococcal
disease among children in a small community, two
of whom attended the same day-care centre,
prompted a programme of mass antibiotic pro-
phylaxis. Nasopharyngeal and throat swabs were
obtained on three occasions from all children
registered at the day-care centre. Serogroup B
Neisseria meningitidis was isolated from 13 of 61
children before prophylaxis, from three children
after 2 weeks, and from 19 children after 3 months.
Repetitive extragenic palindromic PCR analysis
identified several meningococcal strains before
treatment, one of which became predominant after
3 months. Mass antibiotic prophylaxis initially
suppressed meningococcal carriage, but the
carriage rate subsequently rebounded.
Keywords Carriage, children, meningococci, Neisseria
meningitidis, prophylaxis, REP-PCR
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Neisseria meningitidis is a major cause of bacterial
meningitis. Asymptomatic nasopharyngeal colo-
nisation with N. meningitidis occurs in 5–10% of
adults. Molecular subtyping of meningococci can
be used to demonstrate epidemiological links
among patients and carriers, and to monitor the
changing epidemiology of the disease. Repetitive
extragenic palindromic sequence-based PCR
(REP-PCR) has been used successfully to type
various bacteria [1–7], including meningococci
[8–10]. The aim of the present study was to use
REP-PCR to investigate an outbreak of meningo-
coccal disease in a small community in order to
examine the appropriateness of the control meas-
ures applied.
Four children, including three from Netzarim, a
small community of 370 inhabitants in Israel,
were diagnosed with meningococcal meningitis.
Two patients (the first and last cases) were
diagnosed following isolation of N. meningitidis
serogroup B, and the other two cases were
diagnosed clinically. Case definition was based
on the immediate needs of the decision-making
process in the course of the event, and included
high fever, meningitis and ⁄ or petechial rash
during the specified period in Netzarim.
Patient 1, a girl aged 4 years, was diagnosed a
week before patient 2, a girl aged 12 years, with
clinical signs and symptoms of meningococcae-
mia (this patient received ceftriaxone on the way
to hospital). Patient 3, the brother (aged 1.5 years)
of patient 2, developed high fever and upper
respiratory tract symptoms while receiving pro-
phylaxis. Gram-negative cocci were grown from
cerebrospinal fluid culture without final identifi-
cation. Patients 1 and 3 attended the same day-
care centre in Netzarim. Patient 4, a boy aged
17 years from Jerusalem with clinical signs of
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